Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbvie has been a one trick pony that relied heavily on a single drug, Humira, in the past. However, management has been actively expanding the portfolio.

AbbVie: No Longer A One Trick Pony

AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.

AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions

AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.

AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints

NORTH CHICAGO, Ill. and BUDAPEST, Hungary, March 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc.

AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

AbbVie's cash flow and yield are finally getting some respect.

AbbVie Is Still Cheap

NORTH CHICAGO, Ill., March 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily (QD) and 30 mg twice daily (BID) doses, across the 12-week treatment period.

AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine

Bristol-Myers

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Pfizer

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

7 Drug Stocks to Consider After the Viatris Plunge

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

What's in Store for These 3 Big Pharma Outperformers in 2022?

Genmab - ADR

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

Amgen

American Tower

Blackstone Group

Caterpillar

Comcast

Morgan Stanley

If you're a long-term investor you need top-quality dividend stocks in your portfolio. That doesn't mean big yields as much as reliable ones.

7 Dividend Stocks to Finance Your Golden Years

Alcoa

Chevron

Freeport-McMoRan

Coca-Cola

Lockheed Martin

Raytheon Technologies

It's hard to believe, but there are uptrend stocks out there. Investors just have to look for the strength that these stocks are showing.

8 Strong Uptrend Stocks to Buy on the Next Dip

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie (NYSE: ABBV) that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira® (adalimumab) in the United States. The settlement grants Alvot

Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech's Proposed High-Concentration Biosimilar (AVT02) for Humira®

NORTH CHICAGO, Ill., March 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech.

AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech

Of the $17 billion in annual sales that will be lost to copycat drugs this year, a Bristol-Myers Squibb Co. ( BMY , Financial) cancer medication is in line to take the biggest hit.

Blockbusters From Bristol-Myers, AbbVie Losing Exclusivity

Abbvie, Inc. (ABBV) Presents at Cowen Health Care Broker Conference Call - (Transcript)

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?

Global financial markets are going through extreme volatilities, with the market fluctuating more than 2% and the VIX index exceeding its 95% percentile.

AbbVie Inc.: Hunker Down And Hedge Up With Its 3.8% Dividend

Algonquin Power & Utilities

Costco

Energizer Holdings

Could these defensive stocks be your best defense against stock market volatility?

4 Defensive Stocks To Watch As Russia-Ukraine War Intensifies

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Up 6.9% Since Last Earnings Report: Can It Continue?

The multibillionaire's trash could be regular income-investors' treasure.

1 Stock Warren Buffett Is Selling That Income Investors Should Consider Buying

The structure of AbbVie Inc.‘s ( ABBV , Financial) buyout of a clinical-stage biotechnology company this week may be indicative of the type of deals we're going to see more of. The Chicago-area company back-loaded the acquisition of privately held Syndesi Therapeutics, paying $130 million initially, with the opportunity for shareholders of the Belgium-based company to collect another $870 million if predetermined milestones are achieved.

AbbVie Acquisition Strengthens Its Neuroscience Portfolio

AbbVie offers investors a market-beating dividend yield even as it trades near its all-time high.

Is This Dividend King a Buy for 2022 and Beyond?

We think AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects.

Here's Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock

Morningstar

Paylocity Hlds

Lordstown Motors

Reliance Steel & Aluminum

Although the Bank of Canada raised its key lending rate to 0.5% on Wednesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced.

News for AbbVie Stock (ABBV)